NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 6.80 against a street estimate of 4.91 — a beat of 38.5%.
with an average price target of ₹1,703.07.
| Holder | Stake |
|---|---|
| Mirae Asset Large & Midcap Fund | 4.33% |
| New World Fund Inc | 4.28% |
| Anukar Projects | 3.24% |
| Smallcap World Fund, Inc | 2.77% |
| Barclays Wealth Trustees India | 1.55% |
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 LAURUS LABS LIMITED – Q1 FY2027 RESULTS SUMMARY HEADLINE NUMBERS • Revenue: ₹2,026 crore in Q1 FY27, up 29% year-on-year and 12% quarter-on-quarter | 2026-07-24 |
| Quarterly results · Q1 FY27 LAURUS LABS LIMITED – Q1 FY2027 FINANCIAL SUMMARY HEADLINE NUMBERS CONSOLIDATED (Quarter ended June 30, 2026) • Revenue from operations: ₹2,026.31 c | 2026-07-24 |
| Annual report FY2026 LAURUS LABS LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue FY 2025-26: ₹6,813 crore, up 23% year-over-year • EBITDA: ₹1 | 2026-06-08 |
| Q4 FY26 earnings call LAURUS LABS LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Total Revenue FY26: INR 6,813 crores, growth of 23% YoY • Q4 FY26 Revenue: INR 1,812 crores | 2026-05-05 |
| Quarterly results · Q4 FY26 LAURUS LABS LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Full Year FY2025-26 Revenue from Operations: ₹6,812.90 Cr (vs ₹5,553 | 2026-04-30 |
| Investor presentation LAURUS LABS LIMITED – FY2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total Revenue FY26: ₹6,813 Cr, up 23% YoY (₹5,554 Cr in FY25) • Q4 FY26 Re | 2026-04-30 |
| Quarterly results | 2026-04-28 |
| Q3 FY26 earnings call LAURUS LABS LIMITED Q3 FY'26 SUMMARY HEADLINE NUMBERS • Q3 FY'26 Revenue: Rs. 1,778 crores, growth of 26% year-on-year • 9-Month FY'26 Revenue: Rs. | 2026-01-28 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.20 / share ex-date May 8, 2026 | 2026-05-08 |
| Dividend | ₹0.80 / share ex-date Oct 31, 2025 | 2025-10-31 |
| Announcement | Date |
|---|---|
| Update on acquisition Laurus Labs invested ₹107.8 crore in its joint venture KRKA Pharma through a rights issue, acquiring 10.78 crore shares at ₹10 each. After the investment, Laurus Labs holds 26.215 crore KRKA | 2026-10-14 |
| Update on acquisition announced Laurus Labs invested ₹12.10 crore in Kurnool Renewables Private Limited (KRPL) through a rights issue, acquiring 1,20,96,050 equity shares with a face value of ₹10 each. After the investment | 2026-10-06 |
| Update on acquisition of another business or strategic combination Laurus Labs Limited has informed the Exchange about Update on Acquisition | 2025-12-23 |
| Update on acquisition of another business or strategic combination Laurus Labs Limited has informed the Exchange about Update on Acquisition | 2025-12-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Laurus Labs Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.